Skip to main content

CORRECTION article

Front. Med., 10 March 2023
Sec. Dermatology
Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1171132

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

This article is a correction to:

  1. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

    1. Read original article
\nAlexander EgebergAlexander Egeberg1Joseph F. MerolaJoseph F. Merola2Knut SchkelKnut Schäkel3Luis PuigLuis Puig4Patrick D. Mahar,Patrick D. Mahar5,6Isabella Yali WangIsabella Yali Wang5Imre PavoImre Pavo5Christopher Schuster,Christopher Schuster5,7Christopher E. M. Griffiths Christopher E. M. Griffiths8*
  • 1Bispebjerg and Frederiksberg Hospital, Copenhagen University, Copenhagen, Denmark
  • 2Division of Rheumatology, Department of Dermatology and Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States
  • 3Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany
  • 4Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  • 5Eli Lilly and Company, Indianapolis, IN, United States
  • 6Department of Dermatology, Royal Children's Hospital, Faculty of Medicine, Nursing and Health Sciences, Skin Health Institute, The University of Melbourne, Melbourne, VIC, Australia
  • 7Department of Dermatology, Medical University of Vienna, Vienna, Austria
  • 8Dermatology Centre, Salford Royal Hospital, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom

A corrigendum on
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

by Egeberg, A., Merola, J. F., Schäkel, K., Puig, L., Mahar, P. D., Wang, I. Y., Pavo, I., Schuster, C., and Griffiths, C. E. M. (2023). Front. Med. 9:1092688. doi: 10.3389/fmed.2022.1092688

In the published article, there was an error regarding the Conflict of Interest for Patrick D. Mahar, Christopher Schuster, Imre Pavo, and Isabella Yali Wang. The Conflict of Interest statement should be:

AE has honoraria as consultant and/or speaker from AbbVie, Almirall, Bristol-Meyers Squibb, Leo Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. LP has received honoraria/consultation fees from Abbvie, Almirall, Amgen, Baxalta, Boehringer Inglheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Norvartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB. LP has participated in company sponsored speaker's bureau for Celgene, Janssen, Lilly, MSD, Norvartis and Pfizer. KS is a consultant, investigator, speaker and has received grants from: AbbVie, Amgen, Almirall, Biogen, Bristol-Myers Squibb Boehringer Ingelheim, Celgene, Chugai, Galderma, Janssen-Cilag, Leo-Pharma, Lilly, Merck Sharp & Dohme Corp., Morphosys, Novartis, Pfizer, Regeneron, UCB Pharma. JM is a consultant and/or investigator for Amgen, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi-Regeneron, Sun Pharma, Biogen, Pfizer and Leo Pharma. CG has received honoraria or research grants from AbbVie, Almirall, Anaptysbio Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, GSK, Janssen, LEO Pharma, Pfizer, Novartis ONO Pharmaceuticals, UCB Pharma and Walgreens Boots Alliance, and is supported in part by the Manchester NIHR Biomedical Research Centre. PM has served as a consultant, investigator, speaker and/or advisor for Novartis, AstraZeneca, Abbvie, Pfizer, Bristol-Meyers Squibb, Eli Lilly and Company and Boehringer Ingelheim. PM, CS, IP, and IW are employees of Eli Lilly and Company. PM owns equity in Eli Lilly and Company. CS, IP, and IW are minor shareholders of Eli Lilly and Company.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: moderate-to-severe psoriasis, type 2 diabetes, prediabetes, ixekizumab, obesity

Citation: Egeberg A, Merola JF, Schäkel K, Puig L, Mahar PD, Wang IY, Pavo I, Schuster C and Griffiths CEM (2023) Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Front. Med. 10:1171132. doi: 10.3389/fmed.2023.1171132

Received: 21 February 2023; Accepted: 22 February 2023;
Published: 10 March 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Egeberg, Merola, Schäkel, Puig, Mahar, Wang, Pavo, Schuster and Griffiths. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Christopher E. M. Griffiths, Christopher.Griffiths@manchester.ac.uk

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.